A5093883117- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- T-cell and Retrovirus Studies
- Multiple Myeloma Research and Treatments
- Renal Transplantation Outcomes and Treatments
- Organ Donation and Transplantation
- Vector-Borne Animal Diseases
- Animal Disease Management and Epidemiology
- Neutropenia and Cancer Infections
- Cancer Treatment and Pharmacology
- Blood groups and transfusion
- Eosinophilic Disorders and Syndromes
- Organ Transplantation Techniques and Outcomes
- Immunodeficiency and Autoimmune Disorders
Albert Einstein College of Medicine
2024-2025
Montefiore Medical Center
2024-2025
6514 Background: Mutations in the tumor suppressor TP53 gene are common elderly patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) confer resistance to conventional chemotherapeutic DNA damaging agents. Venetoclax (Ven) added hypomethylating agents (HMA) of Decitabine or Azacitidine is current standard care for AML frequently used high-risk MDS (HR-MDS). Currently approved dosing schedules HMA/Ven rely on cytotoxicity have not improved outcomes mutant population....
e19011 Background: Chimeric antigen receptor (CAR) T-cell therapy for B-cell lymphomas is increasing in use and predictive tools, like CAR-HEMATOTOX, help identify patients at risk prolonged neutropenia (NP). This tool, validated two cohorts, lacks confounding by race, but applicability to minority populations unknown. Here we describe hematologic toxicities evaluate possible predictors of toxicity who received axicabtagene ciloleucel (AC) a majority population. Methods: We conducted...